Edwards Lifesciences Corporation, a leader in heart valve therapies and critical care monitoring, is headquartered in the United States. Founded in 1958, the company has established itself as a pioneer in the medical technology industry, particularly in the development of innovative solutions for patients with cardiovascular diseases. With a strong presence in North America, Europe, and Asia, Edwards Lifesciences focuses on advanced heart valve replacement and repair technologies, as well as haemodynamic monitoring systems. Their flagship products, including the transcatheter aortic valve replacement (TAVR) systems, are renowned for their unique design and effectiveness, significantly improving patient outcomes. Recognised for its commitment to innovation, Edwards Lifesciences has achieved numerous accolades, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in cardiac care, enhancing the quality of life for patients worldwide.
How does Edwards Lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Edwards Lifesciences's score of 50 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Edwards Lifesciences reported total greenhouse gas emissions of approximately 15,682,000 kg CO2e for Scope 1 and about 22,393,000 kg CO2e for Scope 2, resulting in a combined total of around 38,075,000 kg CO2e for both scopes. For the UK in 2023, the company disclosed total emissions of about 989,616 kg CO2e, with Scope 1 emissions at approximately 52,607 kg CO2e and Scope 3 emissions contributing significantly, particularly from business travel (about 461,861 kg CO2e) and upstream transportation (approximately 451,630 kg CO2e). Edwards Lifesciences has set ambitious climate commitments, aiming for carbon neutrality by 2030. This includes a target to reduce absolute Scope 1 and 2 emissions by 42% from a 2021 baseline. Additionally, the company plans to decrease Scope 3 emissions by 51.6% per USD of value added within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to transitioning to renewable energy sources for the majority of their global electricity demand. The company has made significant strides in emissions reduction, with a focus on increasing the efficiency of operations and investing in renewable energy solutions. As part of their strategy, Edwards Lifesciences is committed to enhancing the efficiency of their high-volume valve assembly lines and implementing various methods for renewable energy generation.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 4,977,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | - | - | - | - | - | - | - | 00,000,000 |
Scope 2 | 23,498,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | - | - | - | - | 00,000,000 |
Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | - | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Edwards Lifesciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.